Terms: = Prostate cancer AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Treatment
11 results:
1. prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.
Hernandez KM; Venkat A; Elbers DC; Bihn JR; Brophy MT; Do NV; La J; Liu Q; Prokhorenkov A; Metoki-Shlubsky N; Sung FC; Paller CJ; Fillmore NR; Grossman RL
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38050021
[TBL] [Abstract] [Full Text] [Related]
2. Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in prostate cancer.
Qin L; Chung YM; Berk M; Naelitz B; Zhu Z; Klein E; Chakraborty AA; Sharifi N
Cancer Res; 2022 Jul; 82(13):2417-2430. PubMed ID: 35536859
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
[TBL] [Abstract] [Full Text] [Related]
4. Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1α in prostate cancer Cells.
Biswas K; Sarkar S; Said N; Brautigan DL; Larner JM
Mol Cancer Ther; 2020 Apr; 19(4):1008-1017. PubMed ID: 31848297
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity vhl E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract] [Full Text] [Related]
6. [Structural and functional analysis of tumor genomes and the development of test systems for early diagnosis, prognosis and cancer therapy optimization].
Zaletaev DV; Strel'nikov VV; Nemtsova MV; Babenko OV; Kuznetsova EB; Zemliakova VV; Kekeeva TV; Mikhaĭlenko DS; Tanas AS; Rudenko VV; Babaian AIu; Alekseeva EA; Simonova OA
Vestn Ross Akad Med Nauk; 2013; (9):7-14. PubMed ID: 24624866
[TBL] [Abstract] [Full Text] [Related]
7. Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo.
Nardinocchi L; Pantisano V; Puca R; Porru M; Aiello A; Grasselli A; Leonetti C; Safran M; Rechavi G; Givol D; Farsetti A; D'Orazi G
PLoS One; 2010 Dec; 5(12):e15048. PubMed ID: 21179202
[TBL] [Abstract] [Full Text] [Related]
8. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
[TBL] [Abstract] [Full Text] [Related]
9. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.
Thomas SL; Zhong D; Zhou W; Malik S; Liotta D; Snyder JP; Hamel E; Giannakakou P
Cell Cycle; 2008 Aug; 7(15):2409-17. PubMed ID: 18682687
[TBL] [Abstract] [Full Text] [Related]
10. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract] [Full Text] [Related]
11. Precancerous lesions in the kidney.
Van Poppel H; Nilsson S; Algaba F; Bergerheim U; Dal Cin P; Fleming S; Hellsten S; Kirkali Z; Klotz L; Lindblad P; Ljungberg B; Mulders P; Roskams T; Ross RK; Walker C; Wersäll P
Scand J Urol Nephrol Suppl; 2000; (205):136-65. PubMed ID: 11144893
[TBL] [Abstract] [Full Text] [Related]
